Physician profile
Craig W Sapenoff
NPI 1013919802
$1,590.62
in general payments reported to CMS, 2019-2025
10 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $121 · 2022: $337 · 2024: $166 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $256.06 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $242.98 | 2025 | Nuzyra |
| Nevro Corp. | $203.26 | 2022 | |
| Smith+Nephew, INC. | $177.29 | 2019-2025 | Grafix Pl, Collagenase Santyl, Regranex |
| Shockwave Medical, INC | $164.49 | 2025 | |
| Amgen INC. | $154.77 | 2025 | Krystexxa |
| Acera Surgical, INC. | $150.07 | 2024 | Restrata Wound Matrix |
| Djo, LLC | $121.38 | 2020 | |
| Stability Biologics, LLC | $103.67 | 2025 | |
| Merck Sharp & Dohme LLC | $16.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Sapenoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.